{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06245889",
            "orgStudyIdInfo": {
                "id": "J2395"
            },
            "secondaryIdInfos": [
                {
                    "id": "IRB00398141",
                    "type": "OTHER",
                    "domain": "JHM IRB"
                }
            ],
            "organization": {
                "fullName": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                "class": "OTHER"
            },
            "briefTitle": "PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC",
            "officialTitle": "A Pilot Study of Neoadjuvant Response-Adapted Chemotherapy With Pembrolizumab in Patients With Stage 2 and 3 Triple Negative Breast Cancer to Determine Early PET and Biomarker Dynamics",
            "acronym": "NeoADAPT",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "pet-dynamics-to-response-adapted-neoadjuvant-therapy-in-tnbc"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2029-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2030-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-01-23",
            "studyFirstSubmitQcDate": "2024-02-05",
            "studyFirstPostDateStruct": {
                "date": "2024-02-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-06",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Eligible patients with stage 2 and 3 triple negative breast cancer will be treated with 4 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab. A PET scan will be performed at baseline and after 1 cycle of therapy. A breast MRI will be performed after treatment completion. Patients with complete clinical response will proceed to surgery. Patients with clinical residual disease will complete neoadjuvant rescue with 4 cycles of doxorubicin/cyclophosphamide prior to surgery. If residual disease identified after surgery, adjuvant therapy to be determined by the treating oncologist (may include doxorubicin/cyclophosphamide/pembrolizumab, capecitabine etc).",
            "detailedDescription": "Eligible participants will undergo baseline procedures including research bloodwork, MRI and PET scan. Participants will then be treated with one cycle of paclitaxel, carboplatin and pembrolizumab (TCarbo/pembro). At the end of Cycle one patients will undergo repeat procedures (bloodwork and PET scan), and then continue with treatment for an additional three cycles. ctDNA will be collected on day 1 of each cycle. At the end of treatment patients will undergo repeat MRI.\n\nPatients achieving a clinical complete response (CR) on MRI will proceed with surgery. Patients with clinical residual disease (RD) on MRI will be recommended a biopsy, and be recommended \"rescue\" neoadjuvant doxorubicin and cyclophosphamide with pembrolizumab (AC/pembro) for four additional cycles, and then proceed with surgery. Note: patients/treating physician may opt to proceed with surgery.\n\nArchival tissue will be collected from the surgical product. Patients achieving a pathologic CR (pCR) may proceed with adjuvant pembrolizumab per standard of care, and treating physician's discretion. Patients with pathological RD may proceed with \"rescue\" adjuvant AC/pembrolizumab for four additional cycles (if not given neoadjuvantly), per treating physician discretion. The participants may also receive Aadjuvant capecitabine or olaparib as indicated and per treating physician's discretion."
        },
        "conditionsModule": {
            "conditions": [
                "Triple Negative Breast Cancer"
            ],
            "keywords": [
                "breast cancer",
                "triple negative",
                "neoadjuvant"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Eligible patients with stage 2 and 3 TNBC (ER\\<10% eligible) will be treated with 4 cycles of paclitaxel/carboplatin/pembrolizumab prior to surgery. A PET scan will be performed at baseline and after 1 cycle of therapy. A breast MRI will be performed after treatment completion. Patients with complete clinical response will proceed to surgery. Patients with RD will complete neoadjuvant rescue with 4 cycles of doxorubicin/cyclophosphamide prior to surgery. If residual disease identified after surgery, adjuvant therapy to be determined by the treating oncologist (may include doxorubicin/cyclophosphamide/pembrolizumab, capecitabine etc).",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Neoadjuvant therapy",
                    "type": "EXPERIMENTAL",
                    "description": "4 cycles of paclitaxel/carboplatin/pembrolizumab",
                    "interventionNames": [
                        "Drug: Paclitaxel",
                        "Drug: Carboplatin",
                        "Drug: Pembrolizumab",
                        "Drug: Doxorubicin",
                        "Drug: Cyclophosphamide",
                        "Drug: Olaparib",
                        "Drug: Capecitabine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Paclitaxel",
                    "description": "chemotherapy",
                    "armGroupLabels": [
                        "Neoadjuvant therapy"
                    ],
                    "otherNames": [
                        "Taxol"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Carboplatin",
                    "description": "chemotherapy",
                    "armGroupLabels": [
                        "Neoadjuvant therapy"
                    ],
                    "otherNames": [
                        "Paraplatin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "immunotherapy",
                    "armGroupLabels": [
                        "Neoadjuvant therapy"
                    ],
                    "otherNames": [
                        "Keytruda"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Doxorubicin",
                    "description": "additional chemotherapy - neoadjuvant or adjuvant rescue",
                    "armGroupLabels": [
                        "Neoadjuvant therapy"
                    ],
                    "otherNames": [
                        "Adriamycin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "additional chemotherapy - adjuvant rescue",
                    "armGroupLabels": [
                        "Neoadjuvant therapy"
                    ],
                    "otherNames": [
                        "Cytoxan"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Olaparib",
                    "description": "adjuvant rescue",
                    "armGroupLabels": [
                        "Neoadjuvant therapy"
                    ],
                    "otherNames": [
                        "Lynparza"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Capecitabine",
                    "description": "adjuvant rescue",
                    "armGroupLabels": [
                        "Neoadjuvant therapy"
                    ],
                    "otherNames": [
                        "Xeloda"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "SULmax in relation to pCR",
                    "description": "Evaluate if lack of decrease in fluorodeooxyglucose (FDG) / positron emission tomography (PET) standardized uptake value corrected for lean body mass (SULmax) by \\<40% after 1 cycle of neoadjuvant therapy correlates with residual disease at the time of surgery.",
                    "timeFrame": "8 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pathologic complete response (pCR)",
                    "description": "Evaluate the pathologic complete response (pCR) rate in patients with early-stage triple negative breast cancer (TNBC) treated with neoadjuvant chemo-immunotherapy.",
                    "timeFrame": "3 years"
                },
                {
                    "measure": "Circulating tumor deoxyribonucleic acid (ctDNA) clearance",
                    "description": "Evaluate how circulating tumor deoxyribonucleic acid (ctDNA) kinetics collected at pre-treatment, and during and after completion of neoadjuvant treatment correlate with pathologic complete response (pCR) at the time of surgery.",
                    "timeFrame": "3 years"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Pathologic complete response (pCR) comparison",
                    "description": "Compare the pathologic complete response (pCR) rates among patients who achieved clinical complete response (cCR) by breast magnetic resonance imaging (MRI) and those received \"rescue\" neoadjuvant AC/pembrolizumab with clinical residual disease (RD) after MRI scan.",
                    "timeFrame": "3 years"
                },
                {
                    "measure": "Diagnostic accuracy of percent and absolute change between baseline and C1D15 measurements",
                    "description": "Evaluate the diagnostic accuracy of percent and absolute change (between baseline and C1D15 measurements), and C1D15 absolute measurements in fluorodeooxyglucose (FDG) / positron emission tomography (PET) standardized uptake value corrected for lean body mass (SULmax) for predicting clinical complete response (cCR) using receiver operating characteristic (ROC) curve.",
                    "timeFrame": "3 years"
                },
                {
                    "measure": "Clinical complete response (cCR) and pathologic complete response (pCR)",
                    "description": "Investigate if clinical complete response (cCR) by MRI is predictive of pathologic complete response (pCR).",
                    "timeFrame": "3 years"
                },
                {
                    "measure": "Change in microbiome",
                    "description": "Number of patients that experienced changes in the microbiome serially over time of residual disease.",
                    "timeFrame": "3 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Stage II-III TNBC - estrogen receptor (ER) and progesterone receptor (PR) up to and including 10% is eligible\n2. Age \u2265 18 years\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n4. Eligible for standard chemo-immunotherapy as determined by treating physician, including consideration of:\n\n   1. Adequate marrow and organ function\n   2. Co-morbid conditions do not preclude the use of chemo-immunotherapy (such as uncontrolled autoimmune disease, or the use of immunosuppressive medications)\n5. Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study\n\nExclusion Criteria:\n\n1. Patients unable to undergo PET or MRI\n2. Evidence of metastatic disease or loco-regional recurrence (i.e. distant or chest wall recurrence)\n3. Inflammatory breast cancer\n4. Previous treatment with paclitaxel, carboplatin, or immune checkpoint inhibitors",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "genderBased": true,
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Cesar A Santa-Maria, MD",
                    "role": "CONTACT",
                    "phone": "410-614-0874",
                    "email": "csantam2@jhmi.edu"
                },
                {
                    "name": "Hopkins Breast Trials",
                    "role": "CONTACT",
                    "phone": "410-614-1361",
                    "email": "HopkinsBreastTrials@jhmi.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Cesar A Santa-Maria, MD",
                    "affiliation": "Johns Hopkins University",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21287",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Hopkins Breast Trials",
                            "role": "CONTACT",
                            "phone": "410-614-1361",
                            "email": "HopkinsBreastTrials@jhmi.edu"
                        },
                        {
                            "name": "Cesar A Santa-Maria, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21287",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "JHCCCRO",
                            "role": "CONTACT",
                            "phone": "410-955-8866",
                            "email": "jhcccro@jhmi.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "32101663",
                    "type": "RESULT",
                    "citation": "Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549."
                },
                {
                    "pmid": "32966830",
                    "type": "RESULT",
                    "citation": "Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020 Oct 10;396(10257):1090-1100. doi: 10.1016/S0140-6736(20)31953-X. Epub 2020 Sep 20."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                },
                {
                    "id": "D000064726",
                    "term": "Triple Negative Breast Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30373",
                    "name": "Triple Negative Breast Neoplasms",
                    "asFound": "Triple Negative Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017239",
                    "term": "Paclitaxel"
                },
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "D000016190",
                    "term": "Carboplatin"
                },
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                },
                {
                    "id": "D000004317",
                    "term": "Doxorubicin"
                },
                {
                    "id": "D000069287",
                    "term": "Capecitabine"
                },
                {
                    "id": "C000531550",
                    "term": "Olaparib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000000903",
                    "term": "Antibiotics, Antineoplastic"
                },
                {
                    "id": "D000059005",
                    "term": "Topoisomerase II Inhibitors"
                },
                {
                    "id": "D000059003",
                    "term": "Topoisomerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000067856",
                    "term": "Poly(ADP-ribose) Polymerase Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18650",
                    "name": "Carboplatin",
                    "asFound": "System",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7492",
                    "name": "Doxorubicin",
                    "asFound": "Cognitive",
                    "relevance": "HIGH"
                },
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19537",
                    "name": "Paclitaxel",
                    "asFound": "Sessions",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M377",
                    "name": "Capecitabine",
                    "asFound": "200",
                    "relevance": "HIGH"
                },
                {
                    "id": "M233003",
                    "name": "Olaparib",
                    "asFound": "Improvement",
                    "relevance": "HIGH"
                },
                {
                    "id": "M231",
                    "name": "Albumin-Bound Paclitaxel",
                    "relevance": "LOW"
                },
                {
                    "id": "M227339",
                    "name": "Liposomal doxorubicin",
                    "relevance": "LOW"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                },
                {
                    "id": "M29348",
                    "name": "Topoisomerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M205",
                    "name": "Poly(ADP-ribose) Polymerase Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}